Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

BACKGROUND: Arginine-depleting therapy with pegylated arginine deiminase (ADI-PEG20) was reported to have activity in advanced melanoma in early phase I–II trial, and clinical trials are currently underway in other cancers. However, the optimal patient population who benefit from this treatment is u...

Descripción completa

Detalles Bibliográficos
Autores principales: Feun, L G, Marini, A, Walker, G, Elgart, G, Moffat, F, Rodgers, S E, Wu, C J, You, M, Wangpaichitr, M, Kuo, M T, Sisson, W, Jungbluth, A A, Bomalaski, J, Savaraj, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341859/
https://www.ncbi.nlm.nih.gov/pubmed/22472884
http://dx.doi.org/10.1038/bjc.2012.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341859/
https://www.ncbi.nlm.nih.gov/pubmed/22472884
http://dx.doi.org/10.1038/bjc.2012.106

Ejemplares similares